Don’t Miss Out on the AI Gold Rush That’s Just Getting Started

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

Claudine Bruck Biography and Net Worth

Director of Annovis Bio

Dr. Bruck is a pharmaceutical executive and scientist with a strong entrepreneurial drive. Exhibited successes in building a therapeutic research unit de novo and leading discovery and clinical development of biological (vaccines, biopharmaceuticals) and small molecule medicines as well as an ophthalmic drug portfolio. With creativity and a strong results-focus, she is energized to challenge and lead teams. Extensive Pharmaceutical industry experience spans drug discovery and development across several therapeutic.

What is Claudine Bruck's net worth?: The estimated net worth of Claudine Bruck is at least $75,953.00 as of May 13th, 2019. Dr. Bruck owns 7,550 shares of Annovis Bio stock worth more than $75,953 as of April 20th. This net worth estimate does not reflect any other assets that Dr. Bruck may own. Learn More about Claudine Bruck's net worth.
How do I contact Claudine Bruck?: The corporate mailing address for Dr. Bruck and other Annovis Bio executives is 1055 Westlakes Drive Suite 300, Berwyn PA, 19312. Annovis Bio can also be reached via phone at 610-727-3913 and via email at [email protected]. Learn More on Claudine Bruck's contact information.
Has Claudine Bruck been buying or selling shares of Annovis Bio?: Claudine Bruck has not been actively trading shares of Annovis Bio within the last three months. Most recently, on Monday, October 11th, Claudine Bruck bought 181 shares of Annovis Bio stock. The stock was acquired at an average cost of $27.66 per share, with a total value of $5,006.46. Learn More on Claudine Bruck's trading history.
Who are Annovis Bio's active insiders?: Annovis Bio's insider roster includes Claudine Bruck (Director), Maria-Luisa Maccecchini (CEO), and Reid McCarthy (Director). Learn More on Annovis Bio's active insiders.

Claudine Bruck Insider Trading History at Annovis Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/11/2021	Buy	181	$27.66	$5,006.46

Claudine Bruck Buying and Selling Activity at Annovis Bio

Annovis Bio Company Overview

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Today's Range

Now: $10.06

$9.62

$10.18

50 Day Range

MA: $10.34

$8.47

$12.20

2 Week Range

Now: $10.06

$5.42

$22.49

Volume

224,762 shs

Average Volume

184,223 shs

Market Capitalization

$110.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59